UK Markets closed

Eisai Co., Ltd. (ESALY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
108.27+4.65 (+4.49%)
At close: 3:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close103.62
Open108.45
Bid0.00 x 0
Ask0.00 x 0
Day's range108.14 - 109.27
52-week range61.95 - 129.79
Volume20,918
Avg. volume44,912
Market cap31.023B
Beta (5Y monthly)0.50
PE ratio (TTM)36.15
EPS (TTM)2.99
Earnings dateN/A
Forward dividend & yield1.51 (2.31%)
Ex-dividend date28 Sept 2020
1y target est114.29
  • Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate
    Zacks

    Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

    Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

  • Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate
    Reuters

    Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate

    Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said. Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.

  • ​​​​​​​Biogen Soars as Alzheimer’s Approval Cheers Investors
    Bloomberg

    ​​​​​​​Biogen Soars as Alzheimer’s Approval Cheers Investors

    (Bloomberg) -- Biogen Inc. shares surged after its controversial Alzheimer’s disease therapy was approved by U.S. regulators, a landmark decision that stands to dramatically change treatment for the debilitating brain condition.The stock gained as much as 64% shortly after the news of the clearance, triggering a brief volatility halt. It ended up 38% at $395.85, the biggest single-day gain since drug officials first said that the treatment appeared effective in November.The Food and Drug Adminis